Benznidazole - Savant HWP/Humanigen

Drug Profile

Benznidazole - Savant HWP/Humanigen

Alternative Names: HWP-002; RO-71051

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Savant HWP
  • Developer Humanigen; Savant HWP
  • Class Acetamides; Antiprotozoals; Imidazoles
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chagas disease
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Chagas disease

Most Recent Events

  • 08 Aug 2017 Humanigen completes enrolment in clinical trial in Chagas' disease in USA
  • 07 Aug 2017 Humanigen intends to submit a New Drug Application (NDA) to the US FDA for the treatment of Chagas disease in first quarter of 2018
  • 07 Aug 2017 KaloBios Pharmaceuticals is now called Humanigen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top